Charles L. Sawyers, MD, internist and hematologic oncologist; chair of the Human Oncology and Pathogenesis Program; and Marie-Josée and Henry R. Kravis Chair at Memorial Sloan Kettering Cancer Center, discusses the value of atezolizumab (Tecentriq), cobimetinib (Cotellic), and vemurafenib (Zelboraf) in the melanoma treatment landscape.
Archive | Health Professionals
The Importance of IMspire150 Data Is Questioned in Melanoma Treatment Landscape
Posted in Melanoma News, Health Professionals, Video Reports
Study Provides First Evidence That Cancer Metastasis Is Influenced by Inherited Genes
Animal and human studies by scientists at Rockefeller University have for the first time generated data to suggest that an individual’s pre-existing genetic make-up may impact the likelihood of cancer progressing and metastasizing.
Posted in Melanoma News, Health Professionals, Conferences
Blocking tumor signals can hinder cancer’s spread
For most people who die of cancer, the spread of the initial tumor is to blame. “Metastasis is what kills most cancer patients,” says Serge Fuchs, a professor in Penn’s School of Veterinary Medicine.
Posted in Melanoma News, Health Professionals, Conferences
Adjuvant dabrafenib-trametinib provides ‘real chance to cure’ BRAF-mutant melanoma
Adjuvant dabrafenib and trametinib provided long-term benefit for patients with resected stage III BRAF V600-mutant melanoma, according to an analysis of the COMBI-AD trial presented during the ASCO20 Virtual Scientific Program.
Posted in Melanoma News, Health Professionals, Conferences
